Label-free detection of ApoE4-mediated β-amyloid aggregation on single nanoparticle uncovering Alzheimer's disease

Kang, Min Kyung; Lee, Jeewon; Nguyen, Anh H.; Sim, Sang Jun

doi:10.1016/j.bios.2015.05.017

Cited by 59 publications

(29 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detection limit was estimated to be 6 pM by measuring the sensor response to a dilution series and determining the target smallest concentration at which the sensor response is clearly distinguishable from the response to a blank solution. This value is comparable to that achieved by the AgNPs-or AuNPs-based LSPR techniques (0.1 or 1.5 pM), 24,31 and is significantly lower than that achieved by other methods, including molecular beacon (MB; 3.57 nM)-based, 6 graphene oxide (1 nM …”

Section: Sensitivity and Selectivitymentioning

confidence: 47%

“…22,23 Therefore, the direct detection of Aβ oligomer level would be more reliable for AD diagnosis than assay of its monomer. 24,25 Recently, a few novel biosensors have been developed for the detection of Aβ oligomer, including electrochemistry, [26][27][28][29] surface plasma resonance (SPR), 30 localized surface plasmon resonance (LSPR), 24,31 fluorescence, 32,33 nuclear magnetic resonance, 34 and surface-enhanced Raman spectroscopy. 35 These methods are feasible, but they require the use of special instruments and/or relatively expensive and variable antibodies for the capture and recognition of Aβ oligomer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles

Xing¹,

Feng²,

Zhang³

et al. 2017

IJN

View full text Add to dashboard Cite

Soluble beta-amyloid (Aβ) oligomer is believed to be the most important toxic species in the brain of Alzheimer’s disease (AD) patients. Thus, it is critical to develop a simple method for the selective detection of Aβ oligomer with low cost and high sensitivity. In this paper, we report an electrochemical method for the detection of Aβ oligomer with a peptide as the bioreceptor and silver nanoparticle (AgNP) aggregates as the redox reporters. This strategy is based on the conversion of AgNP-based colorimetric assay into electrochemical analysis. Specifically, the peptide immobilized on the electrode surface and presented in solution triggered together the in situ formation of AgNP aggregates, which produced a well-defined electrochemical signal. However, the specific binding of Aβ oligomer to the immobilized peptide prevented the in situ assembly of AgNPs. As a result, a poor electrochemical signal was observed. The detection limit of the method was found to be 6 pM. Furthermore, the amenability of this method for the analysis of Aβ oligomer in serum and artificial cerebrospinal fluid (aCSF) samples was demonstrated.

show abstract

Section: Sensitivity and Selectivitymentioning

confidence: 47%

Section: Introductionmentioning

confidence: 99%

A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles

Xing¹,

Feng²,

Zhang³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…The β-A aggregation is facilitated by an isoform i.e., apolipoprotein E4 (ApoE4) which is also a dominant risk factor for AD progression. An AuNP based biosensor was developed to detect ApoE4 mediated β-A deposition under biological conditions using LPSR (Kang et al 2015). ApoE4 binds with only β-A 1–42 and its specific self-assembled binding onto AuNPs surface due to charge differences was monitored using LSPR shift variation.…”

Section: State-of-the-art Of β-A Detectionmentioning

confidence: 99%

“…This sensor showed a detection limit of 1.5 pM with respect to β-A 1–42 which caused a shift of ~ 2.9 nm LSPR peak. This real time sensing method exhibited a detection limit of 1.5 pM, selective to only β-A 1–42 and could be used to explore interaction of ApoE4-Aβ complexes to optimize therapeutic targeting with label-free manner (Kang et al 2015). …”

Section: State-of-the-art Of β-A Detectionmentioning

confidence: 99%

Nano-biosensors to detect beta-amyloid for Alzheimer's disease management

Kaushik

Jayant

Tiwari

et al. 2016

Biosensors and Bioelectronics

151

View full text Add to dashboard Cite

Beta-amyloid (β-A) peptides are potential biomarkers to monitor Alzheimer’s diseases (AD) for diagnostic purposes. Increased β-A level is neurotoxic and induces oxidative stress in brain resulting in neurodegeneration and causes dementia. As of now, no sensitive and inexpensive method is available for β-A detection under physiological and pathological conditions. Although, available methods such as neuroimaging, enzyme-linked immunosorbent assay (ELISA), and polymerase chain reaction (PCR) detect β-A, but they are not yet extended at point-of-care (POC) due to sophisticated equipments, need of high expertise, complicated operations, and challenge of low detection limit. Recently, β-A antibody based electrochemical immuno-sensing approach has been explored to detect β-A at pM levels within 30–40 minutes compared to 6–8 hours of ELISA test. The introduction of nano-enabling electrochemical sensing technology could enable rapid detection of β-A at POC and may facilitate fast personalized health care delivery. This review explores recent advancements in nano-enabling electrochemical β-A sensing technologies towards POC application to AD management. These analytical tools can serve as an analytical tool for AD management program to obtain bio-informatics needed to optimize therapeutics for neurodegenerative diseases diagnosis management

show abstract

“…Unfortunately, large and efficient SERS enhancements are commonly confined within the nanostructured metal surface, therefore, hampering the direct acquisition of the vibrational spectra of large biomolecules, such as most of the proteins. An AuNP-based biosensor showed a detection limit of 1.5 pM with respect to Aβ 1-42 in detecting ApoE4-mediated Aβ deposition under biological conditions using a localized SPR 10 . Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) is able to detect plasma Aβ in complex mixtures, which might provide better selectivity; however, it is time-consuming and needs sophisticated purifying procedures.…”

Section: Introductionmentioning

confidence: 99%

Highly sensitive/selective 3D nanostructured immunoparticle-based interface on a multichannel sensor array for detecting amyloid-beta in Alzheimer's disease

Liu¹,

Lee²,

Ko³

et al. 2018

Theranostics

View full text Add to dashboard Cite

Accumulation of β-amyloid (Aβ) peptides is highly associated with Alzheimer's disease (AD) progression in prevailing studies. The successful development of an ultrasensitive detection assay for Aβ is a challenging task, especially from blood-based samples.Methods: We have developed a one-step electrophoresis/electropolymerization strategy for preparing a CSIP hierarchical immunoelectrochemical interface that is easily integrated into a PoCT device. The interface includes conductive silk fibroin-based immunoparticles (CSIPs) via electropolymerized Poly(3,4-ethylenedioxythiophene) (PEDOT) bridging to enable on-site electrochemical detection of serum amyloid-β42 (Aβ42) and -β40 (Aβ40) peptides from an AD blood test. In addition, micro-positron emission tomography (microPET) neuroimaging and behavioral tests were simultaneously performed.Results: This nanostructured conductive interface favors penetration of water-soluble biomolecules and catalyzes a redox reaction, providing limits of detection (LOD) of 6.63 pg/mL for Aβ40 and 3.74 pg/mL for Aβ42. Our proof-of-concept study confirms that the multi-sensing electrochemical immunosensor array (MEIA) platform enables simultaneous measurement of serum Aβ42 and Aβ40 peptide levels and is more informative in early stage AD animals than amyloid-labeling Aβ plaque PET imaging and behavioral tests.Conclusion: We believe this study greatly expands the applications of silk fibroin-based materials, is an important contribution to the advancement of biomaterials, and would also be valuable in the design of new types of multichannel electrochemical immunosensor arrays for the detection of other diseases.

show abstract

Label-free detection of ApoE4-mediated β-amyloid aggregation on single nanoparticle uncovering Alzheimer's disease

Cited by 59 publications

References 40 publications

A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles

A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles

Nano-biosensors to detect beta-amyloid for Alzheimer's disease management

Highly sensitive/selective 3D nanostructured immunoparticle-based interface on a multichannel sensor array for detecting amyloid-beta in Alzheimer's disease

Contact Info

Product

Resources

About